ANNA1 Neurological Autoimmunity: A Comparative Analysis of Cancers, Neurological Phenotype and Coexisting Antibodies Across Age Demographics

as having acute symptomatic seizures secondary to autoimmune encephalitis.Electrographic and clinical features associated with the development of acute symptomatic seizures secondary to AE were incorporated into a logistic regression model using a stepwise forward selection model.For patients with acute seizures, a Cox hazard ratio mixed-effect model with time to electro-clinical seizure freedom as the event of interest was performed. ResultsAmong the 102 patients with acute autoimmune encephalitis included, 74 patients (73%) had acute symptomatic seizures: 34 patients with clinical-only seizures, 2 with electrographic-only seizures, and 38 had a combination of clinical and electrographic seizures.Patients with focal slowing, interictal discharges, and periodic discharges were more likely to have electrographic seizures (especially when extra-temporal and with superimposed fast activity), and patients with cell-surface antibodies were more likely to develop either clinical or electrographic seizures after (adjusted odds ratio= 5.00; p=0.01).Patients with LGI1 encephalitis who received sodium channel blockers achieved electro-clinical seizure freedom more rapidly (p<0.05)compared with those on other agents. ConclusionsAcute symptomatic seizures are common in patients with autoimmune encephalitis, especially in those with cell-surface autoantibodies.Antiseizure medications plays a complementary role to immunotherapy to achieving earlier electro-clinical seizure freedom, especially in patients with LGI1 encephalitis.